Global Regulatory Guidelines and Standards for Drugs Used in Pregnancy

Review article

Abstract

Pharmacotherapeutic safety during pregnancy requires equilibrium between treating maternal pathology and preventing fetal harm. The historical stringent pharmaceutical oversight catalyzed by the catastrophic outcomes of the Thalidomide tragedy, established a foundational precedent for rigorous preclinical reproductive toxicity assessment. Current global regulatory structures, spearheaded by the U.S. Food and Drug Administration and the European Medicines Agency, prioritize evidence-based narrative summaries over simplified, legacy risk categories. These modern frameworks integrate animal developmental data, placental transfer studies, and available human clinical observations to inform complex prescribing decisions. Physiological adaptations during gestation including expanded plasma volume, altered hepatic enzyme activity, and increased renal filtration profoundly modify drug pharmacokinetics, requiring trimester-specific dosing adjustments to maintain efficacy. Despite these regulatory advances, a persistent "evidence gap" remains due to the ethical complexities of including pregnant populations in controlled clinical trials. Consequently, healthcare providers frequently rely on post-marketing surveillance and voluntary pregnancy exposure registries to identify rare or delayed adverse outcomes. Future improvements in maternal-fetal safety reside in innovative technologies such as placenta-on-a-chip models and physiologically-based pharmacokinetic modeling. Strengthening global harmonization and adopting precision medicine protocols can optimize therapeutic outcomes while minimizing teratogenic risks. A collaborative effort involving active pharmacovigilance and ethical research expansion is vital for the advancement of maternal health without compromising neonatal development